S

    Sunshine Biopharma Inc (SBFM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.12
    -0.03 (-2.61%)

    Market Cap: $4.46M

    Last updated: Sep 01, 2026 at 4:59 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(4/12)
    Avg Surprise
    -2862.40%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.17 - $-0.17
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.20-17.6%
    60d ago$-0.20-17.6%
    30d ago$-0.20-17.6%
    7d ago$-0.20-17.6%
    Current$-0.17
    Revenue Consensus
    $10M
    Range$10M - $10M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.42
    Range$-0.42 - $-0.42
    1 analysts
    Revenue Consensus
    $9M
    Range$9M - $9M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.42---
    Sep 26EST
    		-$-0.17---
    Jun 26
    Reported Aug 5
    		$-1.15$-1.20+4.17%Beat+70.5%
    Mar 26
    Reported Apr 3
    		$-2.50$-1.60-56.25%Miss-468.2%
    Dec 25
    Reported Feb 25
    		$-0.46$-0.12-283.33%Miss-
    Sep 25
    Reported Nov 13
    		$-1.90$-1.30-46.15%Miss+79.8%
    Jun 25
    Reported Aug 12
    		$-3.90$-1.10-254.55%Miss+99.8%
    Mar 25
    Reported May 15
    		$-0.44$0.07-728.57%Miss+99.9%
    Dec 24
    Reported Mar 31
    		$N/A$0.01N/ABeat-
    Sep 24
    Reported Nov 5
    		$-9.40N/A+99.82%Beat+98.8%
    Jun 24
    Reported Aug 18
    		$-1988.00$-6.00-33033.33%Miss-397.0%
    Mar 24
    Reported May 20
    		$-400.00$-208.00-92.31%Miss-37995.2%
    Dec 23
    Reported Mar 28
    		$-5.00$-3.00-66.67%Miss+99.8%
    Sep 23
    Reported Nov 13
    		$-800.00$-1200.00+33.33%Beat-999900.0%
    Jun 23
    Reported Aug 10
    		$-400.00N/A+75.00%Beat-1333233.3%
    Mar 23
    Reported Apr 4
    		$-1.05N/AN/ABeat-356.5%
    Dec 22
    Reported Dec 31
    		$-2082.06N/AN/ABeat-800892.1%
    Sep 22
    Reported Nov 7
    		$-0.08N/AN/ABeat-700.0%
    Jun 22
    Reported Aug 3
    		$-0.03N/AN/ABeat-200.0%
    Mar 22
    Reported May 6
    		$-0.23N/AN/ABeat-2200.0%
    Dec 21
    Reported Mar 21
    		$0.26N/AN/ABeat+1944.0%
    Sep 21
    Reported Nov 9
    		$-0.01N/AN/ABeat-203.0%
    Jun 21
    Reported Aug 9
    		$-0.01N/AN/ABeat+0.0%
    Mar 21
    Reported May 11
    		$-0.01N/AN/ABeat+0.0%
    Dec 20
    Reported Mar 30
    		$-0.01N/AN/ABeat-464.0%
    Sep 20
    Reported Nov 10
    		$-0.00N/AN/ABeat+75.6%
    Jun 20
    Reported Aug 19
    		$-0.01N/AN/ABeat+76.4%
    Mar 20
    Reported Apr 30
    		$-0.01N/AN/ABeat+62.0%
    Dec 19
    Reported Mar 31
    		$-0.00N/AN/ABeat+94.6%
    Sep 19
    Reported Nov 13
    		$-0.01N/AN/ABeat+79.9%
    Jun 19
    Reported Aug 15
    		$-0.04N/AN/ABeat+88.4%
    Mar 19
    Reported Apr 12
    		$-0.03N/AN/ABeat+89.9%
    Dec 18
    Reported Mar 31
    		$-0.05N/AN/ABeat+58.7%
    Sep 18
    Reported Nov 16
    		$-0.07N/AN/ABeat+27.0%
    Jun 18
    Reported Aug 17
    		$-0.36N/AN/ABeat-461.5%
    Mar 18
    Reported Apr 2
    		$-0.26N/AN/ABeat-14.7%
    Dec 17
    Reported Mar 31
    		$-0.11N/AN/ABeat-16.0%
    Sep 17
    Reported Nov 15
    		$-0.09N/AN/ABeat+92.2%
    Jun 17
    Reported Aug 11
    		$-0.07N/AN/ABeat-
    Mar 17
    Reported Apr 17
    		$-0.23N/AN/ABeat-
    Dec 16
    Reported Mar 31
    		$-0.10N/AN/ABeat-
    Sep 16
    Reported Nov 14
    		$-1.18N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.19EV/EBITDA-7.73x
    Price/FCF-0.29xFCF Yield-350.20%
    Profitability
    Profit Margin-16.50%Operating Margin-17.40%
    ROE-21.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.46xQuick Ratio3.30x
    Trading Statistics
    Beta1.31Avg Volume1.32M
    52-Week High$24.3052-Week Low$1.01

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.17
    SMA 20$1.20
    SMA 50$1.59
    SMA 200$8.31
    EMA 10$1.18
    EMA 20$1.25
    EMA 50$1.97
    EMA 200$7.20

    MACD

    Line: -0.14Signal: -0.19Hist: 0.04

    ADX

    ADX: 23.3+DI: 11.8-DI: 16.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down88.0
    PSAR$1.30

    Bollinger Bands

    Upper Band$1.36
    Lower Band$1.05
    %B Position2537%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    33.8

    Momentum Oscillators

    Stoch %K56.7
    Stoch %D56.4
    Williams %R-63.3
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-61.8
    MFI (14d)87.1

    Volatility Measures

    ATR (14d)$0.18(16.2%)
    StdDev (20d)0.08
    Hist Vol85.6%(High)

    Volume Flow

    VWAP$1.15
    OBV744.4M
    AD Line53.6B
    CMF (20d)0.009

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.24

    Pivot Points

    R3$1.38
    R2$1.33
    R1$1.24
    Pivot Point$1.19
    S1$1.10
    S2$1.05
    S3$0.96

    Advanced Oscillators

    TSI-35.10
    Ultimate Osc50.5
    KST-240.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.26M$8.09M$8.58M$9.42M$9.41M$8.90M$9.59M$8.44M$9.30M$7.54M$7.68M$5.96M
    Cost of Revenue$6.84M$5.91M$5.55M$6.34M$5.99M$6.17M$6.50M$5.57M$6.95M$5.19M$5.11M$3.97M
    Gross Profit$2.43M$2.18M$3.03M$3.07M$3.42M$2.73M$3.09M$2.87M$2.36M$2.35M$2.57M$1.99M
    Operating Expenses$4.04M$3.58M$4.82M$4.16M$5.48M$4.03M$5.18M$3.97M$3.62M$3.70M$3.73M$2.77M
    R&D$13,222$31,724$73,501$119,298$196,232$215,277$149,272$126,362$436,235$222,033$816,328$238,012
    SG&A$1.25M$1.19M$2.02M$909,077$1.62M$1.58M$1.71M$1.13M$855,687$1.31M$2.39M$822,346
    Operating Income$-1,612,858$-1,395,597$-1,790,011$-1,086,613$-2,054,655$-1,295,750$-2,086,903$-1,106,353$-1,268,276$-1,350,589$-1,162,956$-779,474
    Interest Income$48,816$48,426$57,467$75,352$72,715$75,367$99,305$108,614$143,995$144,089$187,613$207,431
    Interest Expense$0$0$0$0$0$0$-40,652$0$245$49,181$54,375$38,527
    Income Before Tax$-1,564,048$-1,243,869$-1,732,553$-1,021,258$-1,980,000$-1,219,932$-2,286,949$-982,586$-837,991$-1,261,448$-1,029,757$-610,530
    Income Tax Expense$0$0$408,374$-137,438$-209,166$-40,161$-128,737$215,217$-343,691$22,353$220,267$40,952
    Net Income$-1,564,048$-1,243,869$-2,140,927$-883,820$-1,770,834$-1,179,771$-2,158,212$-1,197,803$-494,300$-1,283,801$-1,250,024$-651,482
    EBITDA$-1,534,890$-1,215,436$-1,691,439$-1,000,447$-1,980,272$-1,230,506$-2,361,507$-1,026,566$-930,865$-1,313,738$-1,120,642$-742,234
    EBIT$-1,612,864$-1,292,295$-1,790,020$-1,096,610$-2,052,715$-1,295,299$-2,426,906$-1,091,200$-981,741$-1,356,356$-1,162,995$-779,434
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SBFM

    News

    Sunshine Biopharma receives Canadian approval for atenolol tablets

    Sunshine Biopharma Inc. has received Canadian approval for its atenolol tablets in 25mg, 50mg, and 100mg strengths. Atenolol is a generic beta-blocker used for hypertension, angina pectoris, and to improve survival rates after a heart attack. The company plans to distribute the product through its Canadian subsidiary, Nora Pharma Inc., with shipments anticipated by the end of 2026, and aims to launch 12 additional drugs this year.

    Investing.com•8/31/26•
    Bullish

    Sunshine Biopharma Announces Board Vacancy as Dr. Andrew Keller Steps Down After Term Ends

    Sunshine Biopharma Inc. announced that Dr. Andrew Keller will not seek re-election to its board of directors, and his term will conclude at the upcoming annual shareholder meeting. This planned governance transition was communicated on August 25, 2026, with no other leadership changes reported. CEO Dr. Steve N. Slilaty signed the official report on August 28, 2026, confirming Keller's active directorship until his term's expiration.

    Kalkine Media•8/31/26•
    Neutral

    Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

    Sunshine Biopharma has received Canadian regulatory approval for its generic version of Enalapril Maleate, an anti-hypertensive drug. This approval allows the company to enter the global anti-hypertensive drug market, which is projected to reach $25.94 billion by 2030. The company plans to commercialize the drug in Canada and is exploring opportunities in other markets.

    Moomoo•8/19/26•
    Bullish

    BRIEF-Sunshine Biopharma Receives Canadian Regulatory Approval For Enalapril

    Sunshine Biopharma Inc. (SBFM.O) has received Canadian regulatory approval for Enalapril. The company anticipates that shipments of Enalapril to Canadian pharmacies will commence by the end of 2026. This brief announcement highlights a significant step for Sunshine Biopharma in expanding its market presence in Canada.

    Bitget•8/19/26•
    Bullish

    SBFM Looks 55.2% Undervalued on GF Value™ Despite Challenging Fu

    Sunshine Biopharma Inc (SBFM) recently received regulatory approval for its generic Enalapril tablets in Canada, aiming to expand its pharmaceutical offerings. Despite a GF Value™ suggesting the stock is 55.2% undervalued, the company faces significant challenges, including ongoing losses, negative cash flow, and low profitability, resulting in a low GF Score™ of 34/100. Investors are advised to view the undervaluation cautiously, as traditional metrics are not applicable, and no institutional or insider activity indicates strong endorsement.

    GuruFocus•8/19/26•
    Neutral

    Frequently Asked Questions About SBFM

    Does SBFM pay dividends?
    Sunshine Biopharma Inc (SBFM) does not currently pay a regular dividend.
    What is SBFM's market cap?
    Sunshine Biopharma Inc (SBFM) has a market capitalization of $4.46M with a current stock price of $1.12.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In